Novo Holdings

The Novo Holdings Venture Investments team led a $92 million Series A Financing in Kivu Bioscience, an early-stage biotech company developing next-generation antibody-drug conjugate (ADC) programs to deliver therapies that are more effective and safer for cancer patients. The funding will be used to advance Kivu’s multiple oncology programs, including its Topo1i-based ADC pipeline, which is set to begin Phase 1 trials in 2025.   Learn more about Kivu here: https://lnkd.in/eauA6crw #ventureinvestments #biotech #ADC

Today we announced that Novo Holdings led AvenCell's $112 million Series B financing round to support the continued validation of the company’s proprietary Universal Switchable CAR-T cell therapy platform for the treatment of a wide range of hematologic malignancies. In connection with this financing, Novo Holdings Partner Michael Karl Bauer will join AvenCell’s Board of Directors.    Learn more about AvenCell here: https://lnkd.in/ePA9-yud     #ventureinvestments #celltherapy

We are looking for a Junior analyst to support our Legal team on transactions, asset management as well as various internal matters out of our Copenhagen office. As a Junior Analyst you will undertake challenging and varying tasks in relation to carrying out our deliveries to fulfil the legal key strategic initiatives and goals, and to supporting the day-to-day operations of the organisation

Novo Holdings today announced an agreement to acquire a majority stake in Stingray Marine Solutions AS, a market-leading aquaculture technology company that provides advanced solutions for a more sustainable fish farming industry.   The Company’s product, the Stingray system, utilises a combination of camera vision, advanced proprietary software, and laser technology to remove sea lice from fish in a humane and efficient manner. Sea lice are the key driver of salmon health issues, directly or indirectly costing fish farmers €6–7 billion annually.

We are pleased to announce the launch of Booster Therapeutics, a biotechnology company developing a new class of proteasome activator medicines to treat neurodegenerative and other diseases. The launch is accompanied by a $15 million seed financing round led by Apollo Health Ventures and Novo Holdings.   Novo Holdings will play a central role in helping to further build Booster Therapeutics in its next phase of growth, bringing hands-on operational expertise, strategic guidance and helping the company access a larger network of talent.

Novo Holdings is looking for an investment professional with 3-6 years of experience to join our Public Investment team in Copenhagen with a focus on direct credit investments. In this role, you will be responsible for sourcing, analysing, and executing new investments across the leveraged finance spectrum in both public and private credit. You will have the opportunity to learn about companies in various industries and develop expertise in certain areas of interest.

Novo Holdings is looking for an investment professional with 6-9 years of experience to join our Public Investment team in Copenhagen with a focus on direct credit investments. You are passionate about investing and driven by learning. You thrive on research and enjoy creating valuable insights that not only enhance team collaboration, but also lead to better investment decisions.

We are looking for a part-time Senior Legal Counsel to support the legal team and act as an anchor on all legal workstreams out of our Copenhagen office. In the role as Senior Legal Counsel, you will work with certain workstreams related to large M&A transactions, funds and the structural and regulatory setup around them, amongst other things. 

We are looking for an Associate to support our Planetary Health Investments team. As an Associate you’ll play a vital role in analysing global private equity and growth investment opportunities. We offer a unique environment for personal and professional growth, characterised by ambition, dynamism, and professionalism on an international scale.

At Novo Holdings, Engaged Ownership is at the heart of our investment strategy. This weekend we gathered the senior leaders of our life science portfolio companies at our Novo Holdings CEO Life Science Summit to exchange thoughts and ideas of operational and strategic relevance.  #healthcare #sustainability